According to a new report, Houston has potential to lead three life science subsectors: cell and gene therapy manufacturing, molecular diagnostics, and biologics drug development and manufacturing. Photo via Getty Images

A new report found that Houston has great potential across a handful of life science subsectors.

The study by Newmark Consulting Group was commissioned by the Greater Houston Partnership and sponsored by San Jacinto College, Lone Star College, Houston Community College, and McCord Development. It looked at the region's existing resources and value proposition in the life sciences sector.

According to the report, Houston is home to industry-leading expertise in three subsectors: cell and gene therapy manufacturing, molecular diagnostics, and biologics drug development and manufacturing.

From a workforce perspective, the city has a steady flow of new talent from regional universities and "an emerging and robust commitment by community colleges to support two-year degree pathways to meet industry demands and the ability for life science companies to grow and thrive in the market," per the report. The findings led to identifying the next steps for the Houston region to capitalize on these advantages.

“The Newmark study confirms what we knew to be true about the potential for life sciences growth in Houston,” says Susan Davenport, GHP's chief economic development officer, in a news release. “The study will help us coalesce our regional partners around a cohesive strategy to grow and expand the industry in Houston.”

The report's other key findings included:

  • Houston consistently ranks as a top-15 market for life sciences employment nationwide and first in Texas with nearly 700 life science companies operating in town.
  • The Bayou City has the densest patient population in the world, which allows for transformational clinical applications.
  • The city's diverse workforce, extensive university ecosystem, education infrastructure, and research institutions sets a scene for Houston to capture extensive subsector gains.
  • Houston ranks second in the nation in clinical trial volume with more than 4,600 currently active clinical trials, which is representing 15 percent of all active U.S. trials.
  • In 2021, Houston-area institutions attracted $864.1 million in grant funding from the National Institutes of Health, which is up 16.3 percent from 2020. On average over the past five years, the region received $740.7 million per year in NIH funding for a total of $3.9 billion.
  • Houston is home to more than 26,000 non-healthcare life science employees.
  • The region's life sciences workforce ranks No. 12 in the nation, on par with numbers reported for Research Triangle Park.
In light of the report, the GHP is recommending a few action items, including "accelerating workforce development programs to produce new graduates in key life sciences occupations, refining Houston’s marketing messages to highlight the region’s existing life science assets and activities within life science R&D and manufacturing," per the report. Additionally, the GHP identified the need to develop a shared regional strategy to attract and retain leading life sciences companies.
To lead these initiatives, the GHP has assembled task forces, which will be led by the organization’s Life Sciences Committee, chaired by Ferran Prat, senior vice president of Industry Relations and Research at MD Anderson Cancer Center.
Houston — home to the largest medical center — ranks No. 13 on a list of top life science labor markets. Photo via TMC

Here's how Houston ranks as a life science market, according to a new report

by the numbers

For Houston’s life sciences sector, 13 is a very lucky number.

The Houston metro area ranks 13th in CBRE’s first-ever analysis of the country’s top 25 U.S. labor markets for life sciences. Houston’s collective brain power helped cement its place on the list.

The Boston-Cambridge area tops the ranking. Houston is the highest-ranked Texas market, ahead of No. 16 Dallas-Fort Worth and No. 18 Austin.

Dallas-based CBRE, a provider of commercial real estate services, lauds Houston for its “attractive combination” of affordability and a deep pool of Ph.D.-level talent, as well as the presence of major research universities and medical institutions.

Scott Carter, senior vice president of life sciences and healthcare in CBRE’s Houston office, says those factors make Houston “an attractive market for life sciences industry expansion.”

“Houston is projected to lead the nation in population growth over the next five years, which will only strengthen the appeal of its labor market,” Carter says.

Houston boasts the nation’s highest wages in the life sciences sector compared with the cost of living, the analysis shows. Meanwhile, Ph.D. recipients account for 18.5 percent of the 1,300 biological and biomedical sciences degrees granted each year in the Houston area — the highest concentration nationwide. And Houston produces 4.2 percent of such Ph.D. recipients in the U.S. — more than all but a few major life sciences markets do.

“Millions of square feet and billions of dollars of life sciences development is underway or planned in Houston to break down longtime silos between commercial, academic, and medical sectors,” Carter says. “Leveraging the unmatched scale of the Texas Medical Center, these new moon-shot investments are building a launchpad to rocket Space City into a new era as a global hub for scientific and human progress.”

Underscoring the rapid rise of the city’s innovation ecosystem, Houston enjoys one of the country’s fastest-growing pipelines for VC funding in life sciences. Here, VC funding in the sector rose 937 percent in the past five years, compared with the nationwide increase of 345 percent, according to CBRE.

For its analysis, CBRE assessed each market based on several criteria, including its number of life sciences jobs and graduates, its share of the overall job and graduate pool in life sciences, its number of Ph.D. recipients in life sciences, and its concentration of jobs in the broader professional, scientific, and technical services professions.

In 2020, CBRE ranked Houston as the No. 2 emerging hub for life sciences in a report, which factored in size and growth of life-sciences employment, the venture capital and National Institutes of Health funding, and more.

Atul Varadhachary, managing partner of Fannin Innovation Studio, says that now is the time to invest in life sciences. Photo via Getty Images

Innovation studio aims to put Houston on the map for life science startup development

fostering innovation

In a report last year from commercial real estate services company JLL, Boston took the crown for hosting the country's top life sciences ecosystem. Houston ranked 11th.

The difference between Houston and Boston "is not the innovation, it's not the technology, it's not the money. It's that we don't have experienced life sciences entrepreneurs," says Dr. Atul Varadhachary, managing partner of Houston's Fannin Innovation Studio, a for-profit entity that commercializes biotech and medtech concepts.

Fannin has tried to replicate Boston's robust life sciences ecosystem "in a really, really tiny way" via its fellowship program, Varadhachary says. But the reach of the program could be even greater, he believes.

Varadhachary makes a case for tripling or even quadrupling the number of participants in Fannin's federally accredited fellowship program. He says this one relatively small investment could push Houston closer to Boston in the life sciences stratosphere.

Atul Varadhachary is the managing partner of Houston's Fannin Innovation Studio. Photo via fannininnovation.com

To be sure, Houston is no slouch in life sciences. For instance, commercial real estate services company CBRE issued a report last fall ranking Houston second among the country's top emerging clusters for life sciences. But cities like Boston, San Francisco, and San Diego still reign as life sciences royalty in the U.S.

Fannin typically taps five people at a time — folks who've recently earned a master's degree, medical degree or PhD — for a two-year fellowship in life sciences entrepreneurship and commercialization. The initiative is comparable to a post-doctorate program in research or medicine. The Fannin fellows collaborate with therapeutics and medical device companies in the studio's portfolio, gaining hands-on training in facets of business like R&D, intellectual property, regulatory matters, and financing.

Today, five fellows and seven interns work at Fannin. The fellowship program launched in 2006; the internship program started a year earlier. In all, Fannin has welcomed more than 250 fellows and interns. Some of them have gone on to work at Houston organizations such as TMC Innovation, MD Anderson Cancer Center, and the University of Houston.

Varadhachary believes boosting the fellowship headcount to perhaps 15 instead of the current five would be a small price to pay to help elevate Houston's status in life sciences. The full cost of each fellowship is less than $100,000 a year, so bringing aboard another 10 fellows would require an extra annual commitment of under $1 million. That kind of money isn't in Fannin's budget, though.

"I can think of nothing that could give a bigger return on investment for the city," Varadhachary says of expanding Fannin's fellowship program.

More fellows would mean more entrepreneurs equipped to run or start life sciences businesses in Houston, he says. Varadhachary acknowledges the value of efforts like the soon-to-open TMC3 life sciences hub and the recently opened Ion entrepreneurship hub, but he'd like to see more emphasis placed on nurturing people and not just startups.

Varadhachary says the "the one single thing" that Houston could do to increase its probability of success in life sciences, particularly in therapeutics, would be to crank up cultivation of entrepreneurial talent.

"By and large, I don't think know that this community appreciates how important and how under-resourced that whole people-development piece is," he says. "It's not something that comes from taking classes or watching. It comes from doing."

Andrea Letkeman, director of professional development at Fannin, says the fellows initially work one-on-one with a senior executive on projects, then eventually graduate to running their own projects. Fellows also get a close-up look at other projects underway at Fannin.

Varadhachary wants to get Fannin fellows excited "about what we're doing in Houston, and then give them an opportunity to be part of our ecosystem."

Some Fannin fellows have been hired on a full-time basis by the studio, or they've moved into jobs at venture capital firms, life sciences startups, or other players in the ecosystem, according to Letkeman. She says the fellows lend "energy and vibrancy" to Fannin.

"I think that the Fannin model is fairly unique for Houston. There are models that are similar, across the country, to what we do. But there's not enough of them, quite frankly, for the number of people that are interested in these kinds of roles," Letkeman says.

"There is talent that is looking for a way to bridge the gap between academia and real-world commercialization," she adds. "There's just not enough opportunities out there for them."

Kevin Coker, CEO of Proxima Clinical Research, say his company transform from uncertainty to almost uncontrollable growth in just 12 months. He shares what happened on this week's episode of the Houston Innovators Podcast. Photo courtesy of Proxima

Houston health tech company bounces back from COVID-19 in a big way

HOUSTON INNOVATORS PODCAST EPISODE 82

The pandemic hit life science innovation hard. And no one knows that better than Kevin Coker, co-founder and CEO of Proxima Clinical Research, a Houston-based contract research organization focused on supporting life science startups as they grow and scale.

"Last year from January to June, it was very tough," Coker says on this week's episode of the Houston Innovators Podcast. "Hospitals shut down, so any existing projects we had ongoing just halted."

Coker and his team of 12 — including co-founder and chairman, Larry Lawson — at the time didn't have any new projects coming in and were at the mercy of the pandemic.

"Everything was flat. In May, I was starting to worry. I didn't know how long we were going to have to weather the storm," Coker remembers.

Then, in June, things started changing, he says. As hospitals started to reopen and clinical research was reignited. Initially, some COVID diagnostic products were gaining momentum, as well as some emergency use authorization products.

"Things just really started taking off for us," Coker says. "I think it was really a product of investors and people being able to make decisions despite the pandemic."

Coker describes the experience not as a rollercoaster — it was all downhill for Proxima and then business took flight. Last quarter, the company was signing a new contract every two to three days. With the influx of projects, Coker says his team scaled to 50 full time employees and 75 part time team members — most of these new additions Coker hasn't even met yet, since the staff has been working remotely.

"We're a good barometer for what's happening not only locally but across the country," Coker says. "As Proxima has grown, it's really show how the Houston life science market is growing."

Now, Coker is focused on maintaining the company culture at Proxima as well as finding a new, larger office space in the Texas Medical Center — Proxima's current office is in the TMC Innovation Institute.

Coker says it's his intention to keep its operations smaller and more hands on than the usual CRO, which typically has 5,000 to 10,000 employees and multi-billion dollars in revenue, and focused on startups and small companies.

"That type of organization doesn't work well with a small med device or pharmaceutical company. We wanted to create a company that looked and felt like the startups," he says.

Coker shares more about Proxima's growth and Houston's potential of being a major life science hub on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston ranks No. 2 for share of AI talent in professional services

AI surge

Houston’s professional and business services sector—think law, accounting, consulting, and engineering firms—grabs one of the industry’s biggest shares of AI talent.

A report from commercial real estate services giant CBRE ranks Houston No. 2 among the top 50 U.S. and Canadian tech markets for the concentration of AI talent in professional and business services.

Houston’s share of AI talent in professional and business services stands at 26 percent, the report shows. Washington, D.C., tops the list at 31 percent. At 25 percent, Dallas-Fort Worth claims the No. 3 spot.

CBRE based the AI ranking on data from the LinkedIn networking platform.

The company’s researchers tallied 11,709 AI-related tech jobs in Houston. Nationwide, data scientists lead AI-related job growth in the U.S., according to the report.

“AI software and hardware developers are currently the most sought-after tech talent by employers,” the report says.

Houston faces AI talent gap

DoubleTrack, a provider of AI and data consulting, reported in June that Houston faces an AI talent gap.

“The places where businesses say they will adopt AI over the next six months, well ahead of where they are today, are mostly the same places already short on talent: Miami, Houston, and Denver among the metros, South Dakota and South Carolina among the states,” DoubleTrack said.

This labor shortage comes amid Houston’s ascent as an AI hub. For instance, a factory being built here by AI chipmaker NVIDIA and electronics manufacturer Foxconn will produce AI supercomputers and infrastructure systems.

Houston’s place in the sphere of tech talent

Overall, Houston ranks No. 32 in the CBRE report among the top 50 U.S. and Canadian markets for tech talent. The San Francisco Bay Area claims the top spot, with Austin at No. 5 and DFW at No. 8.

CBRE relied on 13 metrics to rank tech talent markets, including concentration of tech talent, tech talent pipeline, and research-and-development investments.

Here are other Houston details from the report:

  • In 2025, Houston’s tech talent workforce numbered 104,080, up 7.3 percent over the past three years.
  • Houston’s average wage for tech talent within the tech industry was $120,216 in 2025, up 13.3 percent over the past three years.

New pilot program for air taxis, Project Nexus, takes flight in Texas

Project Nexus

By 2029, Texas skies could be buzzing with air taxis, much like they are with drones today.

To kick off the "Project Nexus" pilot program in Texas, U.S. Transportation Secretary Sean Duffy, U.S. Sen. Ted Cruz, and Texas Department of Transportation officials attended an event September 10 at Fort Worth Alliance Airport, which serves as the launchpad for a statewide pilot program that could result in air taxis, self-piloted planes, and vertical take-off-and-landing aircraft permanently buzzing across the skies of Texas.

It was the first demonstration in Texas of next-generation aircraft under the pilot program; Texas is the sixth state to participate in the program.

Air taxi service on the radar
The federal government has teamed up with aviation companies BETA Technologies and Joby Aviation, as well as the Texas Department of Transportation, to develop regional air taxi service in Dallas, Austin, San Antonio, and eventually Houston.

Roger Venables, Fort Worth’s aviation director, said in January that he foresees regular air taxi service becoming a reality in the next five years.

On September 12, a Joby-made electric air taxi took a roundtrip flight between Fort Worth Alliance and Dallas Fort Worth International Airport to test flight operations.

The mission was part of a five-day test involving Fort Worth Alliance and DFW Airport flights, and flights over the Fort Worth Stockyards, Toyota Motor North America’s Plano headquarters, and other sites.

A new facility at Fort Worth Alliance will be Joby’s long-term home for regional flight operations.

Building a 'framework' for electric aircraft
TxDOT said Project Nexus is aimed at creating “a scalable system” to connect urban areas, rural communities, and neighboring states as air mobility technology advances.

In a TxDOT release, Marc Williams, the agency’s executive director, said the pilot program will “build a framework for how electric aircraft could one day connect people, goods, and communities across the state.”

Three-phase project will test flight capabilities

Initial flights in the third-year pilot program won’t carry passengers, according to TxDOT. Instead, the flights will gather data, validate air travel routes, and help improve the safety of air mobility technology.

The first phase of the U.S. Department of Transportation’s Project Nexus will feature piloted aircraft such as helicopters and fixed-wing planes. CultureMap previously reported Plano-based VertiPorts by Atlantic, which develops takeoff and landing sites for airplane-helicopter hybrids, would be part of Project Nexus.

The second phase will involve testing airborne medical and cargo logistics. This includes transporting critical medical supplies or donor organs between rural and urban hospitals in the Austin and San Antonio areas.

In the third and final phase, passengers will fly aboard air taxis across the Texas Triangle. Dallas-Fort Worth, Austin, Houston, and San Antonio anchor the triangle.

“In Texas, we don’t wait for the future to arrive, we build it,” Cruz said in the TxDOT release. “The Lone Star State is pushing the boundaries by testing the next generation of aircraft through Project Nexus.”

“These technologies will connect communities, expand access to jobs and services, and strengthen supply chains,” the senator added. “What starts in Texas will help shape the future of aviation throughout the entire country.”

---

This article originally appeared on CultureMap.com.

Houston-area NASA contractor plans Nasdaq IPO

going public

Webster-based NASA contractor Rothe Development Inc. has filed paperwork with the U.S. Securities and Exchange Commission to go public.

Rothe, a minority- and woman-owned business, hasn’t yet identified how many shares it will sell and how much money its IPO might raise. Rothe plans to offer Class B common stock on the Nasdaq exchange.

CEO Karen Wheeler-Hall owns all of the Class A shares and would retain majority control after the IPO, according to the SEC filing. The company plans to use $2.4 million of the IPO proceeds so Wheeler-Hall can pay off a loan from the seller for her 2021 acquisition of Rothe.

From last December to this May, the company raised about $2.1 million in a pre-IPO private placement at $1 per share, the SEC filing shows.

Rothe runs NASA training lab in Houston

Founded in 1967, Rothe supplies engineering, technology, operations and technical services to NASA, the U.S. Department of Defense, other federal agencies, commercial space operators, and regulated industries.

Rothe is likely best known for operating NASA’s Neutral Buoyancy Laboratory in Houston. The lab trains astronauts for spacewalks and simulates space missions. It supports NASA’s International Space Station and Artemis programs.

Company sees room for growth

In the SEC filing, Rothe said it operates in several expanding markets driven by rising investments, including space exploration, national security, cybersecurity and digital infrastructure.

“We believe these market trends create significant opportunities for continued growth across both government and commercial sectors,” the company said.

Rothe generated nearly $126.4 million in revenue last year, up from $117.3 million the previous year. However, the company swung to a $700,000 operating loss in 2025 versus $1.8 million in operating income in 2024.

At the end of 2025, Rothe’s workforce comprised 385 employees and 25 subcontractors. The company also works in the cybersecurity, computer engineering, software development, multimedia and communication, and commercial calibration sectors, according to its website.